Quick Takeaways
- Capital Research Global Investors filed SCHEDULE 13G/A for Vertex Pharmaceuticals Inc. Common Stock (VRTX).
- Disclosed ownership: 6.8%.
- Date of event: 31 Dec 2025.
Capital Research Global Investors - 31 Dec 2025 SCHEDULE 13G/A Report for Vertex Pharmaceuticals Inc. Common Stock (VRTX)
- Filing Manager
- Capital Research Global Investors
- Reporting Manager
- Capital Research Global Investors
- Symbol
- VRTX
- Shares outstanding
- 254,691,824 shares
- Disclosed Ownership
- 17,319,044 shares
- Ownership
- 6.8%
- Form type
- SCHEDULE 13G/A
- Filing time
- 12 Feb 2026, 10:25:43 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 13 May 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Capital Research Global Investors disclosed 6.8% ownership in Vertex Pharmaceuticals Inc. Common Stock (VRTX) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 13 May 2025.
- Current filing was accepted on 12 Feb 2026, 10:25.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Capital Research Global Investors | 6.8% | 17,319,044 | 17,303,696 | 0 | Jae Won Chung | Vice President and Senior Counsel II, Capital Research and Management Company |